1TT

0.002

100%

AZL

0.005

-28.6%

M2R

0.004

100%

CTT

0.475

-27.5%

RDS

0.005

66.7%

AGD

0.056

-20%

AVR

7.5

53.7%

GT1

0.032

-20%

RLG

0.006

50%

OSL

0.004

-20%

MKL

0.007

40%

VRC

0.004

-20%

PDN

5.56

39.7%

SCN

0.017

-19%

AAU

0.004

33.3%

REE

0.031

-18.4%

VKA

0.008

33.3%

GDG

4.13

-16.9%

29M

0.15

30.4%

AJL

0.005

-16.7%

SRZ

0.018

28.6%

AQX

0.005

-16.7%

CU6

2.29

26.9%

KAL

0.045

-16.7%

ARV

0.01

25%

KPO

0.005

-16.7%

KNI

0.175

25%

SPD

0.24

-15.8%

PEC

0.015

25%

ADG

0.006

-14.3%

DYL

1.025

22.8%

NWM

0.012

-14.3%

JAT

0.52

22.4%

BUR

0.05

-13.8%

WOA

0.028

21.7%

AVC

0.45

-13.5%

LOT

0.17

21.4%

GHM

0.385

-13.5%

NIM

0.076

20.6%

WMG

0.13

-13.3%

BlinkLab (ASX:BB1): Partners with US based

Published on Friday May 3 2024

YouTube Video VVVFRVZOQ01GU1J4RmEwQmIyd0tMUzBnLjBodGpKVHFzZnNj

BlinkLab (ASX:BB1) has initiated a clinical study in partnership with US based Turning Pointe Autism Foundation.

The data obtained during the course of this collaboration will be used to finalise the data collection and processing algorithms as well as AI/ML models ahead of the FDA registrational study expected to start in the second half of 2024.

BlinkLab is an innovative digital healthcare company developing smartphone-based AI powered diagnostic tests for autism.

Read the ASX announcement: https://yourir.info/resources/3449d9aa01a61c6b/announcements/bb1.asx/6A1205872/BB1_BlinkLab_Partnership_with_Turning_Pointe_Autism_Foundation.pdf #BB1